Irinotecan and temozolomide in combination with dasatinib and rapamycin versus irinotecan and temozolomide for patients with relapsed or refractory neuroblastoma (RIST-rNB-2011): a multicentre, open-label, randomised, controlled, phase 2 trial
Titel:
Irinotecan and temozolomide in combination with dasatinib and rapamycin versus irinotecan and temozolomide for patients with relapsed or refractory neuroblastoma (RIST-rNB-2011): a multicentre, open-label, randomised, controlled, phase 2 trial
Auteur:
Corbacioglu, Selim Lode, Holger Ellinger, Susanne Zeman, Florian Suttorp, Meinolf Escherich, Gabriele Bochennek, Konrad Gruhn, Bernd Lang, Peter Rohde, Marius Debatin, Klaus Michael Steinbach, Daniel Beilken, Andreas Ladenstein, Ruth Spachtholz, Rainer Heiss, Peter Hellwig, Dirk Tröger, Anja Koller, Michael Menhart, Karin Riemenschneider, Markus J Zoubaa, Saida Kietz, Silke Jakob, Marcus Sommer, Gunhild Heise, Tilman Hundsdörfer, Patrick Kühnle, Ingrid Dilloo, Dagmar Schönberger, Stefan Schwabe, Georg von Luettichau, Irene Graf, Norbert Schlegel, Paul-Gerhardt Frühwald, Michael Jorch, Norbert Paulussen, Michael Schneider, Dominik T Metzler, Markus Leipold, Alfred Nathrath, Michaela Imschweiler, Thomas Christiansen, Holger Schmid, Irene Crazzolara, Roman Niktoreh, Naghmeh Cario, Gunnar Faber, Joerg Demmert, Martin Babor, Florian Fröhlich, Birgit Bielack, Stefan Bernig, Toralf Greil, Johann Eggert, Angelika Simon, Thorsten Foell, Juergen